BBIO Form 144: Founder share sale of 250K shares via Morgan Stanley

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) filed a Form 144 disclosing a proposed sale of 250,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $11,512,420.00 and total shares outstanding reported as 191,168,504. The securities were acquired as founder shares on 07/01/2019 from the issuer and payment was recorded on that date. The filing reports no securities sold during the past three months. The notice includes the required representation about no undisclosed material adverse information. The document does not provide identifying filer contact details or a listed plan adoption date for any Rule 10b5-1 trading plan.

Positive

• Proposed sale is being handled through a registered broker, Morgan Stanley Smith Barney LLC, indicating an orderly brokerage process.
• Filing states the securities were acquired as founder shares with the acquisition and payment dated 07/01/2019, providing clear provenance of the shares.

Negative

• The filing notifies a proposed insider sale of 250,000 common shares with an aggregate market value of $11,512,420.00, which may be viewed negatively by some investors.
• The document does not include identifying filer contact details or CIK information, reducing transparency about the seller.
• No date is provided for adoption of a Rule 10b5-1 trading plan, so it is unclear whether the sale is covered by a pre-established plan.

Insights

Financial Analyst

TL;DR: Form 144 shows an insider sale of 250,000 BBIO shares valued at $11.5M; disclosure appears routine and likely limited market impact.

The filing identifies a single proposed sale executed through a major broker and confirms the shares were originally issued as founder shares in 2019. The aggregate value is disclosed and there were no reported sales in the prior three months, which reduces the appearance of accelerated insider distribution. Absent additional context on the filer’s holdings or motive, this disclosure alone is unlikely to be materially market-moving but is relevant to monitor for further insider activity.

Corporate Governance Expert

TL;DR: Rule 144 notice complies with procedural disclosure but lacks some filer identification details, which weakens transparency.

The form documents compliance with Rule 144 mechanics and includes the required representation about material nonpublic information. It clearly states acquisition origin and payment dates for the securities. However, the absence of explicit filer identity/contact information and no indicated 10b5-1 plan adoption date limits transparency for stakeholders seeking to assess intent and timing. Governance scrutiny should focus on whether fuller disclosure is available elsewhere.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	250000	11512420.00	191168504	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2019	Founder Shares	Issuer			250000	07/01/2019	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for BridgeBio (BBIO) disclose?

The Form 144 discloses a proposed sale of 250,000 common shares via Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $11,512,420.00 and reported outstanding shares of 191,168,504.

Who originally acquired the shares being sold in the BBIO Form 144?

The shares were acquired as founder shares on 07/01/2019 from the issuer, with payment recorded on 07/01/2019.

Were there any BBIO securities sold by this person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Is there a Rule 10b5-1 plan date indicated for this sale in the filing?

No. The form includes the standard representation about Rule 10b5-1 but does not list a date of plan adoption or instruction in the provided content.

Does the Form 144 provide the filer’s contact or CIK details?

The provided document does not include explicit filer identification, CIK, or contact information in the visible content.